Report Thumbnail
Product Code LP0913511473XCA
Published Date 2023/3/10
English120 PagesGlobal

Global Bradycardia Market Growth (Status and Outlook) 2023-2029Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP0913511473XCA◆The Mar 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/3/10
English 120 PagesGlobal

Global Bradycardia Market Growth (Status and Outlook) 2023-2029Pharmaceutical_LifeSciense Market



Abstract


Summary

This report studies Bradycardia, including atropine, isoproterenol, aminophylline, ephedrin, scopolamine, pacemaker, implantable cardioverter defibrillator.
LPI (LP Information)' newest research report, the “Bradycardia Industry Forecast” looks at past sales and reviews total world Bradycardia sales in 2022, providing a comprehensive analysis by region and market sector of projected Bradycardia sales for 2023 through 2029. With Bradycardia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bradycardia industry.
This Insight Report provides a comprehensive analysis of the global Bradycardia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bradycardia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bradycardia market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bradycardia and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bradycardia.
The global Bradycardia market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Bradycardia is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Bradycardia is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Bradycardia is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Bradycardia players cover Alchem International, Alkaloids Corporation, Biotronik, Boston Scientific, Cook Medical, CR Double-Crane, Fine Chemicals Corporation, GlaxoSmithKline and Hangzhou Vega, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Bradycardia market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Atropine
Isoproterenol
Aminophylline
Ephedrin
Scopolamine
Pacemaker
Implantable Cardioverter Defibrillator
Segmentation by application
Sinus Bradycardia
Sinus Cardiac arrest
Sinus Atrial Block
Atrioventricular Block
Sinus Node Syndrome
Acute Myocardial Infarction
Hypothyroidism
Increased Intracranial Pressure
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alchem International
Alkaloids Corporation
Biotronik
Boston Scientific
Cook Medical
CR Double-Crane
Fine Chemicals Corporation
GlaxoSmithKline
Hangzhou Vega
HENAN PURUI
Henry Schein
Katsura Chemical
Lepu Medical
Livanova
Medarex
Medico
Medtronic
Merck
Minsheng Group
Nexus Pharmaceuticals
Nihon Kohden
Oscor
Pfizer
PHILIPS HEALTHCARE
Phytex Australia
Sanofi
Shree Pacetronix
TorquePharma
ZOLL Medical Corporation

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Bradycardia Market Size 2018-2029
      • 2.1.2 Bradycardia Market Size CAGR by Region 2018 VS 2022 VS 2029
    • 2.2 Bradycardia Segment by Type
      • 2.2.1 Atropine
      • 2.2.2 Isoproterenol
      • 2.2.3 Aminophylline
      • 2.2.4 Ephedrin
      • 2.2.5 Scopolamine
      • 2.2.6 Pacemaker
      • 2.2.7 Implantable Cardioverter Defibrillator
    • 2.3 Bradycardia Market Size by Type
      • 2.3.1 Bradycardia Market Size CAGR by Type (2018 VS 2022 VS 2029)
      • 2.3.2 Global Bradycardia Market Size Market Share by Type (2018-2023)
    • 2.4 Bradycardia Segment by Application
      • 2.4.1 Sinus Bradycardia
      • 2.4.2 Sinus Cardiac arrest
      • 2.4.3 Sinus Atrial Block
      • 2.4.4 Atrioventricular Block
      • 2.4.5 Sinus Node Syndrome
      • 2.4.6 Acute Myocardial Infarction
      • 2.4.7 Hypothyroidism
      • 2.4.8 Increased Intracranial Pressure
    • 2.5 Bradycardia Market Size by Application
      • 2.5.1 Bradycardia Market Size CAGR by Application (2018 VS 2022 VS 2029)
      • 2.5.2 Global Bradycardia Market Size Market Share by Application (2018-2023)
  • 3 Bradycardia Market Size by Player

    • 3.1 Bradycardia Market Size Market Share by Players
      • 3.1.1 Global Bradycardia Revenue by Players (2018-2023)
      • 3.1.2 Global Bradycardia Revenue Market Share by Players (2018-2023)
    • 3.2 Global Bradycardia Key Players Head office and Products Offered
    • 3.3 Market Concentration Rate Analysis
      • 3.3.1 Competition Landscape Analysis
      • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
    • 3.4 New Products and Potential Entrants
    • 3.5 Mergers & Acquisitions, Expansion
  • 4 Bradycardia by Regions

    • 4.1 Bradycardia Market Size by Regions (2018-2023)
    • 4.2 Americas Bradycardia Market Size Growth (2018-2023)
    • 4.3 APAC Bradycardia Market Size Growth (2018-2023)
    • 4.4 Europe Bradycardia Market Size Growth (2018-2023)
    • 4.5 Middle East & Africa Bradycardia Market Size Growth (2018-2023)
  • 5 Americas

    • 5.1 Americas Bradycardia Market Size by Country (2018-2023)
    • 5.2 Americas Bradycardia Market Size by Type (2018-2023)
    • 5.3 Americas Bradycardia Market Size by Application (2018-2023)
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Bradycardia Market Size by Region (2018-2023)
    • 6.2 APAC Bradycardia Market Size by Type (2018-2023)
    • 6.3 APAC Bradycardia Market Size by Application (2018-2023)
    • 6.4 China
    • 6.5 Japan
    • 6.6 Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
  • 7 Europe

    • 7.1 Europe Bradycardia by Country (2018-2023)
    • 7.2 Europe Bradycardia Market Size by Type (2018-2023)
    • 7.3 Europe Bradycardia Market Size by Application (2018-2023)
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Bradycardia by Region (2018-2023)
    • 8.2 Middle East & Africa Bradycardia Market Size by Type (2018-2023)
    • 8.3 Middle East & Africa Bradycardia Market Size by Application (2018-2023)
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Global Bradycardia Market Forecast

    • 10.1 Global Bradycardia Forecast by Regions (2024-2029)
      • 10.1.1 Global Bradycardia Forecast by Regions (2024-2029)
      • 10.1.2 Americas Bradycardia Forecast
      • 10.1.3 APAC Bradycardia Forecast
      • 10.1.4 Europe Bradycardia Forecast
      • 10.1.5 Middle East & Africa Bradycardia Forecast
    • 10.2 Americas Bradycardia Forecast by Country (2024-2029)
      • 10.2.1 United States Bradycardia Market Forecast
      • 10.2.2 Canada Bradycardia Market Forecast
      • 10.2.3 Mexico Bradycardia Market Forecast
      • 10.2.4 Brazil Bradycardia Market Forecast
    • 10.3 APAC Bradycardia Forecast by Region (2024-2029)
      • 10.3.1 China Bradycardia Market Forecast
      • 10.3.2 Japan Bradycardia Market Forecast
      • 10.3.3 Korea Bradycardia Market Forecast
      • 10.3.4 Southeast Asia Bradycardia Market Forecast
      • 10.3.5 India Bradycardia Market Forecast
      • 10.3.6 Australia Bradycardia Market Forecast
    • 10.4 Europe Bradycardia Forecast by Country (2024-2029)
      • 10.4.1 Germany Bradycardia Market Forecast
      • 10.4.2 France Bradycardia Market Forecast
      • 10.4.3 UK Bradycardia Market Forecast
      • 10.4.4 Italy Bradycardia Market Forecast
      • 10.4.5 Russia Bradycardia Market Forecast
    • 10.5 Middle East & Africa Bradycardia Forecast by Region (2024-2029)
      • 10.5.1 Egypt Bradycardia Market Forecast
      • 10.5.2 South Africa Bradycardia Market Forecast
      • 10.5.3 Israel Bradycardia Market Forecast
      • 10.5.4 Turkey Bradycardia Market Forecast
      • 10.5.5 GCC Countries Bradycardia Market Forecast
    • 10.6 Global Bradycardia Forecast by Type (2024-2029)
    • 10.7 Global Bradycardia Forecast by Application (2024-2029)
  • 11 Key Players Analysis

    • 11.1 Alchem International
      • 11.1.1 Alchem International Company Information
      • 11.1.2 Alchem International Bradycardia Product Offered
      • 11.1.3 Alchem International Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.1.4 Alchem International Main Business Overview
      • 11.1.5 Alchem International Latest Developments
    • 11.2 Alkaloids Corporation
      • 11.2.1 Alkaloids Corporation Company Information
      • 11.2.2 Alkaloids Corporation Bradycardia Product Offered
      • 11.2.3 Alkaloids Corporation Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.2.4 Alkaloids Corporation Main Business Overview
      • 11.2.5 Alkaloids Corporation Latest Developments
    • 11.3 Biotronik
      • 11.3.1 Biotronik Company Information
      • 11.3.2 Biotronik Bradycardia Product Offered
      • 11.3.3 Biotronik Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.3.4 Biotronik Main Business Overview
      • 11.3.5 Biotronik Latest Developments
    • 11.4 Boston Scientific
      • 11.4.1 Boston Scientific Company Information
      • 11.4.2 Boston Scientific Bradycardia Product Offered
      • 11.4.3 Boston Scientific Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.4.4 Boston Scientific Main Business Overview
      • 11.4.5 Boston Scientific Latest Developments
    • 11.5 Cook Medical
      • 11.5.1 Cook Medical Company Information
      • 11.5.2 Cook Medical Bradycardia Product Offered
      • 11.5.3 Cook Medical Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.5.4 Cook Medical Main Business Overview
      • 11.5.5 Cook Medical Latest Developments
    • 11.6 CR Double-Crane
      • 11.6.1 CR Double-Crane Company Information
      • 11.6.2 CR Double-Crane Bradycardia Product Offered
      • 11.6.3 CR Double-Crane Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.6.4 CR Double-Crane Main Business Overview
      • 11.6.5 CR Double-Crane Latest Developments
    • 11.7 Fine Chemicals Corporation
      • 11.7.1 Fine Chemicals Corporation Company Information
      • 11.7.2 Fine Chemicals Corporation Bradycardia Product Offered
      • 11.7.3 Fine Chemicals Corporation Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.7.4 Fine Chemicals Corporation Main Business Overview
      • 11.7.5 Fine Chemicals Corporation Latest Developments
    • 11.8 GlaxoSmithKline
      • 11.8.1 GlaxoSmithKline Company Information
      • 11.8.2 GlaxoSmithKline Bradycardia Product Offered
      • 11.8.3 GlaxoSmithKline Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.8.4 GlaxoSmithKline Main Business Overview
      • 11.8.5 GlaxoSmithKline Latest Developments
    • 11.9 Hangzhou Vega
      • 11.9.1 Hangzhou Vega Company Information
      • 11.9.2 Hangzhou Vega Bradycardia Product Offered
      • 11.9.3 Hangzhou Vega Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.9.4 Hangzhou Vega Main Business Overview
      • 11.9.5 Hangzhou Vega Latest Developments
    • 11.10 HENAN PURUI
      • 11.10.1 HENAN PURUI Company Information
      • 11.10.2 HENAN PURUI Bradycardia Product Offered
      • 11.10.3 HENAN PURUI Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.10.4 HENAN PURUI Main Business Overview
      • 11.10.5 HENAN PURUI Latest Developments
    • 11.11 Henry Schein
      • 11.11.1 Henry Schein Company Information
      • 11.11.2 Henry Schein Bradycardia Product Offered
      • 11.11.3 Henry Schein Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.11.4 Henry Schein Main Business Overview
      • 11.11.5 Henry Schein Latest Developments
    • 11.12 Katsura Chemical
      • 11.12.1 Katsura Chemical Company Information
      • 11.12.2 Katsura Chemical Bradycardia Product Offered
      • 11.12.3 Katsura Chemical Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.12.4 Katsura Chemical Main Business Overview
      • 11.12.5 Katsura Chemical Latest Developments
    • 11.13 Lepu Medical
      • 11.13.1 Lepu Medical Company Information
      • 11.13.2 Lepu Medical Bradycardia Product Offered
      • 11.13.3 Lepu Medical Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.13.4 Lepu Medical Main Business Overview
      • 11.13.5 Lepu Medical Latest Developments
    • 11.14 Livanova
      • 11.14.1 Livanova Company Information
      • 11.14.2 Livanova Bradycardia Product Offered
      • 11.14.3 Livanova Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.14.4 Livanova Main Business Overview
      • 11.14.5 Livanova Latest Developments
    • 11.15 Medarex
      • 11.15.1 Medarex Company Information
      • 11.15.2 Medarex Bradycardia Product Offered
      • 11.15.3 Medarex Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.15.4 Medarex Main Business Overview
      • 11.15.5 Medarex Latest Developments
    • 11.16 Medico
      • 11.16.1 Medico Company Information
      • 11.16.2 Medico Bradycardia Product Offered
      • 11.16.3 Medico Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.16.4 Medico Main Business Overview
      • 11.16.5 Medico Latest Developments
    • 11.17 Medtronic
      • 11.17.1 Medtronic Company Information
      • 11.17.2 Medtronic Bradycardia Product Offered
      • 11.17.3 Medtronic Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.17.4 Medtronic Main Business Overview
      • 11.17.5 Medtronic Latest Developments
    • 11.18 Merck
      • 11.18.1 Merck Company Information
      • 11.18.2 Merck Bradycardia Product Offered
      • 11.18.3 Merck Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.18.4 Merck Main Business Overview
      • 11.18.5 Merck Latest Developments
    • 11.19 Minsheng Group
      • 11.19.1 Minsheng Group Company Information
      • 11.19.2 Minsheng Group Bradycardia Product Offered
      • 11.19.3 Minsheng Group Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.19.4 Minsheng Group Main Business Overview
      • 11.19.5 Minsheng Group Latest Developments
    • 11.20 Nexus Pharmaceuticals
      • 11.20.1 Nexus Pharmaceuticals Company Information
      • 11.20.2 Nexus Pharmaceuticals Bradycardia Product Offered
      • 11.20.3 Nexus Pharmaceuticals Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.20.4 Nexus Pharmaceuticals Main Business Overview
      • 11.20.5 Nexus Pharmaceuticals Latest Developments
    • 11.21 Nihon Kohden
      • 11.21.1 Nihon Kohden Company Information
      • 11.21.2 Nihon Kohden Bradycardia Product Offered
      • 11.21.3 Nihon Kohden Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.21.4 Nihon Kohden Main Business Overview
      • 11.21.5 Nihon Kohden Latest Developments
    • 11.22 Oscor
      • 11.22.1 Oscor Company Information
      • 11.22.2 Oscor Bradycardia Product Offered
      • 11.22.3 Oscor Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.22.4 Oscor Main Business Overview
      • 11.22.5 Oscor Latest Developments
    • 11.23 Pfizer
      • 11.23.1 Pfizer Company Information
      • 11.23.2 Pfizer Bradycardia Product Offered
      • 11.23.3 Pfizer Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.23.4 Pfizer Main Business Overview
      • 11.23.5 Pfizer Latest Developments
    • 11.24 PHILIPS HEALTHCARE
      • 11.24.1 PHILIPS HEALTHCARE Company Information
      • 11.24.2 PHILIPS HEALTHCARE Bradycardia Product Offered
      • 11.24.3 PHILIPS HEALTHCARE Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.24.4 PHILIPS HEALTHCARE Main Business Overview
      • 11.24.5 PHILIPS HEALTHCARE Latest Developments
    • 11.25 Phytex Australia
      • 11.25.1 Phytex Australia Company Information
      • 11.25.2 Phytex Australia Bradycardia Product Offered
      • 11.25.3 Phytex Australia Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.25.4 Phytex Australia Main Business Overview
      • 11.25.5 Phytex Australia Latest Developments
    • 11.26 Sanofi
      • 11.26.1 Sanofi Company Information
      • 11.26.2 Sanofi Bradycardia Product Offered
      • 11.26.3 Sanofi Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.26.4 Sanofi Main Business Overview
      • 11.26.5 Sanofi Latest Developments
    • 11.27 Shree Pacetronix
      • 11.27.1 Shree Pacetronix Company Information
      • 11.27.2 Shree Pacetronix Bradycardia Product Offered
      • 11.27.3 Shree Pacetronix Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.27.4 Shree Pacetronix Main Business Overview
      • 11.27.5 Shree Pacetronix Latest Developments
    • 11.28 TorquePharma
      • 11.28.1 TorquePharma Company Information
      • 11.28.2 TorquePharma Bradycardia Product Offered
      • 11.28.3 TorquePharma Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.28.4 TorquePharma Main Business Overview
      • 11.28.5 TorquePharma Latest Developments
    • 11.29 ZOLL Medical Corporation
      • 11.29.1 ZOLL Medical Corporation Company Information
      • 11.29.2 ZOLL Medical Corporation Bradycardia Product Offered
      • 11.29.3 ZOLL Medical Corporation Bradycardia Revenue, Gross Margin and Market Share (2018-2023)
      • 11.29.4 ZOLL Medical Corporation Main Business Overview
      • 11.29.5 ZOLL Medical Corporation Latest Developments
  • 12 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.